Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Carl Zeiss Meditec AG (OJ:AFX) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Company presents its forward-oriented range of solutions
(Jena, September 12th, 2008) Look forward - this is Carl Zeiss Meditec's motto for the leading European Congress for Ophthalmology ESCRS (European Society of Cataract and Refractive Surgeons). "In the last five years Carl Zeiss Meditec has experienced remarkable development. We've turned into an integrated medical technology company with twelve locations and more than 2000 employees worldwide. And we are now looking forward to maximising the dynamic innovative force which forms the basis of our strong reputation by harnessing the synergies of the extended company. Look forward - applies not only to us but also to our customers. Together with physicians we are pressing ahead with rapid developments in surgical ophthalmology. We will be taking a further step into the future for our customers with first-rate new products which fit seamlessly into our integrated range of solutions," said Dr. Michael Kaschke, President and CEO of Carl Zeiss Meditec, explaining the company's strategy at this year's congress. Carl Zeiss Meditec is using congresses such as the ESCRS, to be held from 13 to 17 September 2008 in Berlin (Germany), not only to present the major new developments; the company will also be offering doctors and media representatives the opportunity to discuss urgent medical issues and possible solutions to these challenges in an informed environment. Numerous wetlabs and scientific workshops will be serving as discussion forums alongside the innovation symposium. There will be demonstration operations performed by leading surgeons which can be monitored live on screens. In its "Meet the Experts" series, internationally recognised specialists will be reporting on their experience with Carl Zeiss Meditec products. The latest generations of intraocular lenses (IOLs) are just some of the new products. With incisions of less than 1.5 mm, Acri.LISA® and Acri.LISAtoric are the first intraocular lenses for true micro incision (MICS) refractive cataract surgery in the world. "These toric and multifocal IOLs are our response to the continually rising demands patients place on their eye surgeons. The technique of microincision dissolves the boundaries between cataract and refractive surgery. In the Acri.LISA® we have brought surgeons' dream of avoiding astigmatism during the procedure one step closer, and are giving the patients the possibility of a life free from spectacles," says Dr. Kaschke, explaining the benefits of this groundbreaking achievement. "We are convinced that offering the complete premium IOL portfolio will put the company at the forefront of microincision surgery". The IOLMaster is used for eye measurement and has successfully established itself on the market over the last ten years. A new, optimised version will be presented at the ESCRS, setting a new benchmark in biometry. The latest generation allows ophthalmologists and their patients to make even more precise and individualised preparation for artificial lens implantation. The OPMI Lumera is a surgical microscope which was developed specifically for ophthalmic surgery. Ever since its launch it has received an overwhelmingly positive response from specialists. Thanks to its patented SCI(TM) technology, high-contrast details in the eye can now be discerned with an unprecedented depth of field. Physicians receive further workflow support in the OR in the form of an information and documentation system specially developed for eye surgery. This is about to receive its European launch at the ESCRS. CALLISTO Eye will present operation-related data at the push of a button. Work loads will fall, information security will rise. CALLISTO Eye also allows the entire operation to be documented in the form of a video recording, i.e. each step before, during and after the operation can be reviewed and reproduced. In Berlin Carl Zeiss Meditec will be celebrating the first anniversary of the installation of the innovative VisuMax® femtosecond laser in the private practices of refractive surgeons. In combination with the high-end MEL 80(TM) excimer laser and the CRS-Master®, the VisuMax® forms a perfectly integrated family of devices for refractive surgery. The system has now been installed in practices al over the world and has received exceptionally positive assessments from users. The ESCRS will also see the unveiling of the new MEL 80(TM) Eye Tracker with a sample rate of 1kHz. This reduces the reaction time of the Eye Tracker by half and optimises the correct positioning of the laser spot. Further applications of the VisuMax laser system are in preparation. Initial study reports have now been published and the new applications can be discussed with experts in Berlin. A major new diagnostic device is the optical coherence tomographer CirrusTM HD-OCT, exploiting the full potential of spectral domain technology. Quick and easy to operate, it provides unique views of the retina thanks to precision segmentation algorithms and high quality live images, thereby forming the best possible basis for reliable diagnosis and treatment decisions for retinal disorders. The ESCRS (European Society of Cataract and Refractive Surgeons) is an association of European eye surgeons which is at the cutting edge of developments in surgery on the anterior part of the eye. The society, founded in 1991, counts 4,000 members from 90 countries worldwide. ESCRS congresses meanwhile make a vital contribution to the exchange of specialized knowledge and expertise between eye specialists.
Brief profile Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's leading medical technology companies. This market position is based on over 160 years of experience in optical innovation. The company has two primary areas of activitiy: In the field of ophthalmology Carl Zeiss Meditec offers integrated solutions for treating the four main eye diseases: vision defects (refraction), cataracts, glaucoma and retinal disorders. The company's system solutions are employed in all phases of the disease management, from diagnosis to treatment and follow-up. Carl Zeiss Meditec has always applied its technological expertise to product innovations. These innovations range from basic systems such as slit lamps and fundus cameras to standard setting diagnostic systems such as the Humphrey® Field Analyzer, the Cirrus(TM) HD-OCT and the IOLMaster®, through to the surgical microscopes and innovative treatment systems in refractive laser surgery. The product portfolio in ophthalmic surgery is rounded off by intraocular lenses and consumables. In the field of neuro and ENT surgery, Carl Zeiss Meditec is the world's leading provider of surgical microscopes and microsurgical visualisation solutions for a very broad range of applications, such as tumor and vascular surgery in the head region and/or spinal surgery. The most recent example of our innovative performance in the area of microsurgery is the OPMI Pentero® visualisation system, which allows efficient and ergonomic patient treatment. Carl Zeiss Meditec will systematically expand its product range in this area and become a solution provider in neuro and ENT surgery as well. Carl Zeiss Meditec's medical technology portfolio is rounded off by visualisation systems for doctors in private practice and promising future technologies such as intraoperative radiation therapy, which allows the targeted treatment of breast cancer and brain cancer directly during surgery. An aging global population, rising expectations of doctors and patients, together with innovative treatment methods in medical technology are expected to promote market growth in the long term. Carl Zeiss Meditec holds an optimum position for future developments in the health sector. The company focuses its solution portfolio on the three medical challenges with a significant social and economic impact: loss of mobility, vision and cognitive abilities. The goal is to deliver technologies and application-oriented solutions that allow doctors to improve the quality of life of their patients and to further improve the efficiency of diagnosis and treatment. Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in Germany (Carl Zeiss Surgical GmbH, Carl Zeiss Meditec Vertriebsgesellschaft mbH, Acri.Tec AG and Carl Zeiss Medical Software GmbH), the USA (Carl Zeiss Meditec, Inc., Dublin California), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain (Carl Zeiss Meditec Iberia S.A., Madrid) and France (Carl Zeiss Meditec S.A.S, La Rochelle, and Carl Zeiss Meditec France SAS, Le Pecq). Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss, one of the world's leading international groups engaged in the optical and opto-electronics industry.
Carl Zeiss Meditec AG Goeschwitzer Strasse 51-52 Jena Germany
WKN: 531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share, TecDAX; Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Geregelter Markt in Frankfurter Wertpapierbörse;
